Study of the Immunity of Patients With Lung Cancer and COVID-19 Infection

Observational, retrospective data collection and prospective IgG analysis, and multicenter study.

The main objective of the study is th description of the characteristics and evolution of patients with lung cancer who have acquired COVID-19 infection.

For the identification of patients who contract COVID-19 infection, the IgG+ blood test by ELISA method will be used.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Lung Cancer COVID COVID-19 Corona Virus Infection Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Respiratory Tract Neoplasms Thoracic Neoplasms Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Complejo Hospitalario de A Coruña, A Coruña, Spain

About this study

Non-post-authorization study, retrospective of data collection and prospective of IgG analysis, observational and multicenter.

The study will be extended to all the sites of the Spanish Lung Cancer Group, more than 170 centers and 500 professionals, and it is expected that around 1,500 IgG tests will be carried out.

The study has three phases:

The scope of phase I is the identification of acquired immunity (IgG) in patients with lung cancer, whether or not they have presented symptoms of having suffered from COVID19. In addition, the description of the characteristics and evolution of patients with lung cancer who have contracted COVID-19 infection will be carried out.

For the identification of patients who contract COVID-19 infection, the IgG+ test in blood will be used by ELISA method.

The scope of phase II is the confirmation of the presence of antibodies (IgG) in patients who tested positive in Phase I of the study a few weeks after the first diagnosis made through the SOLID study.

The scope of phase III is the confirmation of the presence of antibodies (IgG) in patients with lung cancer who have been vaccinated with any of the available and authorized vaccines for SARS-COV2 and 6 months after said administration.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients diagnosed with lung cancer at any stage of the disease
Age ≥ 18
Patients who have signed the informed consent for this study

Exclusion criteria

Patients who have not signed or do not wish to sign the informed consent for this study

Treatment and study plan

IgG test

Diagnostic Test

IgG+ blood test by ELISA method.

Primary outcomes

Description of the characteristics of patients

Time frame: From the diagnosis of the COVID until the determination of the blood IgGs, up to 10 weeks

Description of the characteristics and evolution of patients with lung cancer who have contracted COVID-19 infection.

Secondary outcomes

Detection of antibodies (IgG) at 6 months after SARS-COV2 vaccines

Time frame: From the date of complete SARS-COV2 vaccination administration until 6 month

Confirmation of the presence of antibodies (IgG) in patients with lung cancer who have been vaccinated with any of the available and authorized vaccines for SARS-COV2 and 6 months after such administration.

Sponsors and collaborators

Lead sponsor

Fundación GECP

Other

Registry information

Official study title

Study of Acquired Immunity in Patients With Lung Cancer and COVID-19 Infection

Acronym: SOLID

Important dates

Study start: 2020
Primary completion: 2022
Study completion: 2022
First posted: May 29, 2020
Registry last updated: Feb 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed